Clinical Trial Update: Study of Liatermin (r-metHuGDNF) Administered by Bilateral Intraputaminal (IPu) Infusion to Subjects With Idiopathic Parkinson's Disease [Phase 1]

View source ↗

Summary

The update reports completion of a Phase 1 study of Liatermin (r-metHuGDNF) delivered by bilateral intraputaminal infusion in idiopathic Parkinson's disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Parkinson Disease

Drugs mentioned

• Liatermin (r-metHuGDNF)

Snippet

Sponsor: Amgen | Conditions: Idiopathic Parkinson's Disease | Phase 1 | Status: COMPLETED